Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Four Ways to Optimize Preclinical In Vitro Data to Mitigate Risk of Late-Stage Clinical Failure | Contract Pharma

What are you searching for?

Sign in
Company Blog

Four Ways to Optimize Preclinical In Vitro Data to Mitigate Risk of Late-Stage Clinical Failure

When it comes to planning studies for your drug’s preclinical development, even more due diligence is required because the stakes could be huge.

1. Collect high-quality data to make informed, confident go/no go decisions for moving your drug candidate forward

When it comes to planning studies for your drug’s preclinical development, even more due diligence is required because the stakes could be huge. You can’t just pull into another dealership and drive out with a new molecule. Data quality, expertise of whoever is conducting the study, and confidence in interpretation of results should be at the top of the list for considerations for safety studies because inaccuracies or missed red flags early in development could result in big problems or even failure down the road.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters